Q3 EPS Forecast for Aardvark Therapeutics Reduced by Analyst

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for shares of Aardvark Therapeutics in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.70) per share for the quarter, down from their previous forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.57) EPS.

Several other equities analysts have also commented on AARD. Royal Bank Of Canada reduced their price target on Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Thursday, August 14th. Wall Street Zen lowered Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $32.80.

Aardvark Therapeutics Trading Down 4.9%

NASDAQ AARD opened at $9.67 on Wednesday. The company has a 50-day moving average price of $12.41. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics during the 2nd quarter worth $42,000. Walleye Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the first quarter valued at $88,000. New York State Common Retirement Fund acquired a new stake in shares of Aardvark Therapeutics in the second quarter valued at $99,000. Bank of America Corp DE lifted its holdings in shares of Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after purchasing an additional 3,369 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Aardvark Therapeutics during the first quarter valued at $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.